Inventiva announces a €20.1 million issuance of royalty certificates
Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).Royalty of 3% on future net...
Epidemics
Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System
AUDUBON, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced...
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has...
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone
– Findings reported today in the journal Lancet Infectious Diseases– Study shows synergistic immunological response generated by M2SR and Fluzone High...
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that...
A Single Drug Against Multiple Respiratory Virus Infections – COVID, RSV, Influenza, Bird Flu – Planning Next Phase of Clinical Trials, Says NanoViricides
SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Sapiens Accelerates Growth for Medical Professional Liability Insurers
Sapiens' expanded offering maximizes business value for MPL insurers, supporting growth and retention ROCHELLE PARK, N.J., July 2, 2024...
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in...
Leaders convene to pursue solutions to Wildlife Data Sharing, Bridging the wildlife sector with world-class science to prevent the next pandemic
SEATTLE, June 20, 2024 /PRNewswire/ -- Even as the role of wildlife in disease outbreaks is increasingly recognized, our ability to...
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of...
Goodness Growth Holdings Announces Closing of Recently Announced Non-Brokered Private Placement
– Company also receives short extension of its credit agreement until July 31, 2024 –MINNEAPOLIS, June 17, 2024 (GLOBE NEWSWIRE)...
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%...
Owlet Expands Global Footprint with Launch of Medically-Certified Dream Sock™ in the UK and Across Europe
LEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the UK and...
Eve Communications, Inc. to Showcase at What’s Next Longevity Venture Summit June 11-12, 2024 in San Francisco, California.
Company to share groundbreaking technology at the AgeTech Collaborative from AARP as part of their launch. BROOKLYN, N.Y., June 10,...
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in...
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to...
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma...